Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function.

H Dorai1, B M Mueller, R A Reisfeld

  • 1Abbott Biotech, Inc., Needham Heights, MA 02194.

Hybridoma
|April 1, 1991
PubMed
Summary

Aglycosylated human IgG1 antibodies lack antibody-dependent cell-mediated cytotoxicity (ADCC) but retain complement-dependent cytotoxicity (CDC). Serum half-life and biodistribution remain comparable to native antibodies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The plasminogen receptor<sub>,</sub> Plg-R<sub>KT</sub><sub>,</sub> is essential for mammary lobuloalveolar development and lactation.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Deficiency of plasminogen receptor, Plg-R<sub>KT</sub> , causes defects in plasminogen binding and inflammatory macrophage recruitment in vivo.

Journal of thrombosis and haemostasis : JTH·2016
Same author

MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene.

Oncogene·2013
Same author

Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer.

British journal of cancer·2011
Same author

The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression.

Oncogene·2009
Same author

DNA vaccines suppress angiogenesis and protect against growth of breast cancer metastases.

Breast disease·2005

Area of Science:

  • Immunology
  • Biochemistry
  • Molecular Biology

Background:

  • N-linked glycosylation is crucial for the function of many proteins, including antibodies.
  • The role of glycosylation in the effector functions of human IgG1 antibodies is complex and not fully understood.

Purpose of the Study:

  • To investigate the impact of removing the N-linked glycosylation site on the effector functions of human IgG1 antibodies.
  • To compare the effector functions, serum half-life, and biodistribution of aglycosylated IgG1 antibodies with their native counterparts.

Main Methods:

  • Site-directed mutagenesis was used to eliminate the N-linked carbohydrate attachment site in human IgG1 antibodies.
  • Effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), were assessed.

Related Experiment Videos

  • Serum half-life and biodistribution were evaluated in mice.

    • Main Results:

    • Aglycosylated human IgG1 antibodies completely lost antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
    • A significant level of complement-dependent cytotoxicity (CDC) activity was retained by the aglycosylated antibodies.
    • Serum half-life and biodistribution in mice were comparable between aglycosylated and native IgG1 antibodies.

    Conclusions:

    • N-linked glycosylation critically affects the ADCC activity of human IgG1 antibodies.
    • CDC activity is largely independent of N-linked glycosylation for human IgG1 antibodies.
    • Aglycosylation does not significantly alter the in vivo pharmacokinetics of human IgG1 antibodies.